ArriVent BioPharma, Inc. (AVBP) vs Ultragenyx Pharmaceutical Inc. (RARE)

ArriVent BioPharma, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. ArriVent BioPharma, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.5B and $1.5B). ArriVent BioPharma, Inc. has the higher net margin (0.00% vs −81.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, ArriVent BioPharma, Inc. leads on 6 and Ultragenyx Pharmaceutical Inc. on 4.

Valuation

Metric AVBP RARE Biotechnology median
P/E n/m n/m 7.88
P/S n/m 2.06 11.47
P/B 3.69 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 1.65 10.73
Earnings yield (12.72%) (40.28%) (28.84%)
Free cash flow yield (10.92%) (33.43%) (23.03%)

Profitability

Metric AVBP RARE Biotechnology median
Gross margin — 83.12% 65.16%
Operating margin 0.00% (73.64%) 0.00%
Net margin 0.00% (81.73%) 0.00%
Free cash flow margin 0.00% (68.90%) 0.00%
Return on equity (53.10%) 838.86% (57.72%)
Return on assets (49.30%) (45.60%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AVBP RARE Biotechnology median
Revenue growth (TTM) — 17.51% 5.64%
EPS growth (last fiscal year) (68.75%) 7.31% —
Revenue growth, 5-year CAGR — 19.95% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AVBP RARE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.16 1.73 4.73
Net debt to EBITDA 1.73 1.35 0.96

Dividend

Metric AVBP RARE Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric AVBP RARE Biotechnology median
Market cap 1.48b 1.45b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack